How have FDA drug reviews been affected by initiatives such as Patient-Focused Drug Development and the push for better use of PROs? How is the agency incorporating the patient viewpoint, and what tweaks are likely as part of the next round of user fee negotiations? Catalyst President Nancy Bradish Myers will moderate a panel exploring these questions during the FDA/CMS Summit on Dec. 15. She will be joined by leaders in patient advocacy – Pat Furlong, President/CEO, Parent Project Muscular Dystrophy, and Eleanor Perfetto, SVP, National Health Council – and innovator companies – Gwen Mayers, Deputy Director, Advocacy Relations, Bayer, and Lori Abrams, Director, Diversity & Patient Engagement, Bristol-Myers Squibb.